CD30.CAR-T is named as a drug or biological intervention in 2 clinical trials in our USA trial register, none of which are currently recruiting. The lead sponsor is Tessa Therapeutics. Registered phases: Phase 2 and Phase 1. Conditions studied include Hodgkin Lymphoma, Adult; Hodgkin Disease Recurrent; Hodgkin Disease Refractory.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04268706 | Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) (ClinicalTrials.gov ↗) Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory |
Phase 2 | Active, closed |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (ClinicalTrials.gov ↗) Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Hodgkin Lymphoma, Adult | 1 |
| Hodgkin Disease Recurrent | 1 |
| Hodgkin Disease Refractory | 1 |
| Hodgkin Disease, Pediatric | 1 |
| Anaplastic Large Cell Lymphoma | 1 |
| Peripheral T Cell Lymphoma | 1 |
| Extranodal NK/T-cell Lymphoma | 1 |
| Diffuse Large B Cell Lymphoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Tessa Therapeutics | 2 |
| Register | CD30.CAR-T trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CD30.CAR-T works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CD30.CAR-T (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.